TScan Therapeutics announced an accepted abstract for poster presentation at ASGCT's annual meeting on TCR-engineered therapies for cancer. TScan Therapeutics, Inc., a clinical-stage biotechnology ...
Affimed N.V., a clinical-stage immuno-oncology company, announced that an abstract on its phase 2 LuminICE-203 study involving the innate cell engager acimtamig in combination with AlloNK has been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results